ALEJANDRA RENDON: Open Payments
NPI 1992479018 · EL PASO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,448 in 128 payments from 14 companies in 2025. Trend: 2023 $1,490 · 2024 $1,662 · 2025 $2,448
Food & beverage: $2,448
| Company | Payments | Amount |
|---|---|---|
| Travere Therapeutics, Inc. | 28 | $452 |
| Bayer Healthcare Pharmaceuticals Inc. | 12 | $298 |
| Calliditas Therapeutics US Inc. | 12 | $246 |
| Novo Nordisk Inc | 11 | $237 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 17 | $229 |
| AstraZeneca Pharmaceuticals LP | 9 | $226 |
| SCPHARMACEUTICALS INC. | 13 | $208 |
| Amgen Inc. | 7 | $169 |
| Vifor Pharma, Inc. | 6 | $98 |
| Otsuka America Pharmaceutical, Inc. | 4 | $84 |
Products named: Kerendia, TARPEYO, JARDIANCE, FUROSCIX, KRYSTEXXA, Ozempic, FARXIGA, Filspari.
Industry payments across TX — which companies pay providers there.
